A Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)

Starting soon

Conditions studied: Pneumococcal Infections, Streptococcal Infections, Bacterial Infections

In brief

This clinical study will enroll 100 participants from the 2-month-old (minimum 6 weeks) group who previously participated in the Phase III clinical trial of the 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197, TT vector) (Protocol No.: CS-CTP-PCV), with 50 participants in each of the treatment and control groups, and who have completed blood sample collection for the 1-year and 2-year immunogenicity studies. All participants will have 3.0-3.5 mL of venous blood collected for the immunogenicity study.

Key facts

Study ID
NCT07648641
Run by
CanSino Biologics Inc.
People needed
100
Starts
2026-09-01
Expected to finish
2027-12-01
Last updated by the study team
2026-08-05

Who can join

Age: 5 and older, up to 5. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.